Assenagon Asset Management S.A. Has $9.66 Million Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Assenagon Asset Management S.A. raised its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 152.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 49,030 shares of the medical research company’s stock after purchasing an additional 29,621 shares during the period. Assenagon Asset Management S.A. owned 0.10% of Charles River Laboratories International worth $9,657,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Tortoise Investment Management LLC increased its holdings in shares of Charles River Laboratories International by 77.0% in the second quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 57 shares during the last quarter. Wolff Wiese Magana LLC acquired a new position in shares of Charles River Laboratories International in the third quarter valued at about $32,000. Headlands Technologies LLC acquired a new position in shares of Charles River Laboratories International in the first quarter valued at about $41,000. Whittier Trust Co. of Nevada Inc. grew its stake in shares of Charles River Laboratories International by 219.3% in the second quarter. Whittier Trust Co. of Nevada Inc. now owns 281 shares of the medical research company’s stock valued at $58,000 after acquiring an additional 193 shares in the last quarter. Finally, Sunbelt Securities Inc. grew its stake in shares of Charles River Laboratories International by 1,072.7% in the first quarter. Sunbelt Securities Inc. now owns 258 shares of the medical research company’s stock valued at $70,000 after acquiring an additional 236 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

CRL has been the topic of several research reports. Bank of America downgraded shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating and decreased their price target for the company from $250.00 to $215.00 in a research note on Wednesday, October 2nd. Baird R W cut shares of Charles River Laboratories International from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 8th. Redburn Atlantic initiated coverage on shares of Charles River Laboratories International in a research report on Monday, October 14th. They set a “sell” rating and a $151.00 price objective for the company. TD Cowen cut their price objective on shares of Charles River Laboratories International from $228.00 to $203.00 and set a “hold” rating for the company in a research report on Monday, August 12th. Finally, Robert W. Baird cut their price objective on shares of Charles River Laboratories International from $191.00 to $190.00 and set a “neutral” rating for the company in a research report on Friday, September 20th. Three equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $209.00.

Charles River Laboratories International Stock Performance

Charles River Laboratories International stock opened at $182.12 on Monday. The business has a 50 day moving average of $195.84 and a 200-day moving average of $211.08. Charles River Laboratories International, Inc. has a 1 year low of $161.65 and a 1 year high of $275.00. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.58 and a quick ratio of 1.21. The company has a market capitalization of $9.38 billion, a P/E ratio of 21.43, a P/E/G ratio of 5.11 and a beta of 1.36.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, August 7th. The medical research company reported $2.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.39 by $0.41. The company had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.03 billion. Charles River Laboratories International had a return on equity of 14.96% and a net margin of 10.83%. On average, equities research analysts predict that Charles River Laboratories International, Inc. will post 10.01 earnings per share for the current year.

Charles River Laboratories International announced that its board has authorized a share repurchase plan on Wednesday, August 7th that permits the company to buyback $1.00 billion in shares. This buyback authorization permits the medical research company to reacquire up to 9.6% of its shares through open market purchases. Shares buyback plans are often a sign that the company’s board believes its stock is undervalued.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).